NOTICE OF UPGRADE

Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022

InvestoGain Australia
 

SEARCH LISTED COMPANY


Any AUS or NZ company

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH PRIVATE COMPANY


SEARCH FUNDS

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

SOMNOMED LIMITED (SOM)

Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

 

Shareholder links

Our website ranking of SOM: rating 5
(5 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Boardroom Pty Ltd
Level 8, 210 George Street, Sydney NSW 2000
Tel : +61 2 9290 9600 or 1300 737 760
Fax : +61 2 9279 0664 or 1300 653 459
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000SOM1
Address: Level 3, 20 Clarke Street, CROWS NEST, NSW, AUSTRALIA, 2065
Tel:  (02) 94670 400Fax: (02) 9467 0467

Date first listed: 27/08/2004

Sector: Health Care Equipment & Services Industry Group: XHJ
Activities: Treatment of sleep disorders

News & Events

Expand this box to read and print

The suspension of trading in the securities of SomnoMed Limited will be lifted immediately following the release by SOM of an announcement regarding the results of the institutional component of an accelerated non-renounceable entitlement offer and having noted SOM's prior announcement on Tuesday 9 April 2024 of a trading update and changes to its earnings guidance for the financial year ending 30 June 2024.

10/04/2024

The company has successfully completed the institutional component of its 1 for 1.01 accelerated non-renounceable entitlement offer of new fully paid ordinary shares in the company. The Institutional Entitlement Offer closed on Tuesday, 9 April 2024.

10/04/2024

The company releases a notice of proposed issue of securities.

09/04/2024

The company releases an Investor Presentation.

09/04/2024

The company releases a prospectus for a pro-rata accelerated non-renounceable entitlement offer to Eligible Shareholders of approximately 107.5 million New Shares at an issue price of $0.21 per New Share on the basis of 1 New Shares for every 1.01 Shares held on the Record Date to raise approximately $22.6 million before expenses. The Retail Entitlement Offer closes at 5.00pm AEST on Wednesday, 1 May 2024 (unless extended). Valid acceptances must be received before that date.

09/04/2024

Revised financial year ending 30 June 2024 (FY24) revenue growth guidance of 6% - 9%, versus previous guidance of 12%+, related to inability to meet customer demand due to manufacturing capacity constraints. Revised FY24 EBITDA1 guidance of $(1) - $0 million, versus previous guidance of $3 million+, due to manufacturing constraints and delayed implementation of cost initiatives announced in January 2024. FY24 capex guidance of $5 million, unchanged from previous guidance. SomnoMed is launching a fully underwritten $22.6 million capital raising to clean its balance sheet and reduce costs, and fund investment into manufacturing capacity initiatives and Rest Assure scalability.

09/04/2024

SomnoMed requests that trading in its securities continue to be suspended whilst it prepares a proposed equity capital raising which is proposed to comprise an accelerated entitlement offer as well as to finalise a trading update and a downgrade to the Company's FY24 guidance. "¢ SomnoMed expects that it will announce any Entitlement Offer and revised FY24 guidance on Tuesday 9 April 2024 but requests that the voluntary suspension remain in place until the first to occur of the commencement of normal trading on Wednesday 10 April 2024 and the release of an announcement in relation to the outcome of the institutional component of any Entitlement Offer.

05/04/2024

SomnoMed requests that trading in its securities continue to be suspended whilst it prepares a proposed equity capital raising which is proposed to comprise an accelerated entitlement offer as well as to finalise a trading update and a downgrade to the Company's FY24 guidance. "¢ SomnoMed expects that it will announce any Entitlement Offer and revised FY24 guidance on Tuesday 9 April 2024 but requests that the voluntary suspension remain in place until the first to occur of the commencement of normal trading on Wednesday 10 April 2024 and the release of an announcement in relation to the outcome of the institutional component of any Entitlement Offer.

05/04/2024

The securities of SomnoMed Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of SOM, pending the release of an announcement regarding trading update and earning guidance.

02/04/2024

The suspension of trading in the securities of SomnoMed Limited will be lifted immediately, following the release by SOM of an announcement regarding details of a capital raise and updated guidance.

26/03/2020

The company announces the successful completion of the institutional component of its 1 for 3.24 accelerated non-renounceable entitlement offer of new fully paid ordinary shares in the company. The institutional entitlement offer closed on Wednesday, 25 March 2020. The shortfall from the institutional entitlement offer has been placed to TDM Growth Partners Pty Ltd as well as certain existing institutional shareholders of the company and new institutional investors pursuant to a bookbuild. The retail component of the entitlement offer will raise up to a further approximately $5.8 million.

26/03/2020

The company releases a cleansing notice in relation to its entitlement issue.

25/03/2020

The company releases a notice of Proposed issue of Securities - SOM.

25/03/2020

The company releases an Investor Presentation.

25/03/2020

SomnoMed Limited provides a trading update with regard to the impact of Coronavirus (COVID 19) on the business. SomnoMed con-currently announces a 1 for 3.24 fully underwritten accelerated pro-rata non-renounceable entitlement offer to raise gross proceeds of approximately $15.5 million.

25/03/2020

The securities of SomnoMed Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of SOM, pending the release of an announcement regarding details of a capital raise and updated guidance.

19/03/2020

we understand that on or about this date the company consolidated its shares 1 for 20

27/11/2009

listed entity carried for record purposes only

05/11/2004

this company was previously Indo Pacific Securities Limited, delisted following closure of Second Board market in 1992

05/11/2004

 

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...

     


     

    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    28/02/2023Amrita Blickstead28,359$1.148$32,567
    23/09/2022Hamish Corlett130,094$1.380$179,530
    18/03/2022Neil Verdal-Austin-49,383$1.647$81,337
    29/11/2021Guy Russo217,000$2.300$499,100
    27/09/2021Hamish Corlett53,762$2.400$129,029

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Guy RussoChairman24/08/2020
    Darren CollinsCFO01/08/2023
    Karen BorgExecutive Director, CEO26/11/2020
    Amrita BlicksteadExecutive Director, CEO24/08/2020
    Hamish CorlettDirector01/05/2018
    Michael GordonDirector24/08/2020
    Terence FlitcroftCompany Secretary

    Date of first appointment, title may have changed.

    SPECIAL NOTE: During May 2024 we are working to remove duplications in the Company Secretary role.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Neil Verdal-AustinManaging Director, CEO15/10/200823/02/2024
    Hilton BrettNon Exec Director24/08/202012/10/2023
    Herve FievetCFO08/04/201905/07/2023
    Peter NeustadtNon Exec Chairman13/11/200624/08/2020
    Lee AusburnNon Exec Director15/09/201124/08/2020
    Robert ScheriniNon Exec Director15/09/201124/08/2020
    Derek SmithCEO01/09/201616/11/2018
    Ralf BarschowCEO11/07/200731/07/2012
    Graham HurstNon Exec Director09/06/200605/04/2012
    Paul HopperNon Exec Director01/07/200730/09/2011

    Date of first appointment, title may have changed.